Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
View
Liver Tumours
6
Boston Scientific: SIRT: The versatility of current HCC treatment & the opportunities for the future - Digital Liver Cancer Summit 2021
